Arbutus Biopharma Corp
Chiusa
4.34 0.46
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
4.25
Massimo
4.38
Entrata | 173M 170M |
|---|---|
Vendite | 178M 179M |
P/E Media del settore | 5.398 49.888 |
EPS | 1.19 |
Margine di Profitto | 94.735 |
Dipendenti | 19 |
EBITDA | 177M 169M |
Utili prossimi | 5 ago 2026 |
|---|
Capitalizzazione di Mercato | 20M 885M |
|---|---|
Apertura precedente | 3.88 |
Chiusura precedente | 4.34 |
Arbutus Biopharma Corp Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
Arbutus Biopharma Corp Previsione
Notizie finanziarie
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$
Chi Siamo Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
